|
Clinical trials Methodology/study design
Citations 1-10 of 78 total displayed.
|
Most recent content
(7 Oct 2008):
|
- ARTICLES
Dose comparison trial of sustained-release fampridine in multiple sclerosis
- A. D. Goodman, T. R. Brown, J. A. Cohen, L. B. Krupp, R. Schapiro, S. R. Schwid, R. Cohen, L. N. Marinucci, A. R. Blight For the Fampridine MS-F202 Study Group
Neurology 2008; 71: 1134-1141.
[Abstract]
[Full text]
[PDF]
|
Past content
(since Jan 2001):
|
- EDITORIALS
You get what you measure: Evaluating endpoints in MS clinical trials
- Ruth Ann Marrie
Neurology 2008; 71: 620-621.
[Full text]
[PDF]
- VIEWS AND REVIEWS
The placebo treatments in neurosciences: New insights from clinical and neuroimaging studies
- Nico J. Diederich and Christopher G. Goetz
Neurology 2008; 71: 677-684.
[Abstract]
[Full text]
[PDF]
- ARTICLES
SCA Functional Index: A useful compound performance measure for spinocerebellar ataxia
- T. Schmitz-Hübsch, P. Giunti, D. A. Stephenson, C. Globas, L. Baliko, F. Saccà, C. Mariotti, M. Rakowicz, S. Szymanski, J. Infante, B.P.C. van de Warrenburg, D. Timmann, R. Fancellu, R. Rola, C. Depondt, L. Schöls, E. Zdzienicka, J. -S. Kang, S. Döhlinger, B. Kremer, B. Melegh, A. Filla, and T. Klockgether
Neurology 2008; 71: 486-492.
[Abstract]
[Full text]
[PDF]
- EDITORIALS
The muddle of mycophenolate mofetil in myasthenia
- Michael Benatar and Lewis P. Rowland
Neurology 2008; 71: 390-391.
[Full text]
[PDF]
- ARTICLES
A trial of mycophenolate mofetil with prednisone as initial immunotherapy in myasthenia gravis
- The Muscle Study Group
Neurology 2008; 71: 394-399.
[Abstract]
[Full text]
[PDF]
- ARTICLES
Measuring progression in frontotemporal dementia: Implications for therapeutic interventions
- C. M. Kipps, P. J. Nestor, C. E. Dawson, J. Mitchell, and J. R. Hodges
Neurology 2008; 70: 2046-2052.
[Abstract]
[Full text]
[PDF]
- EDITORIALS
Responsiveness and predictive values in PPMS: An uncertain message
- Gary R. Cutter and Fred D. Lublin
Neurology 2008; 70: 1061-1062.
[Full text]
[PDF]
- ARTICLES
Responsiveness and predictive value of EDSS and MSFC in primary progressive MS
- J. J. Kragt, A. J. Thompson, X. Montalban, M. Tintoré, J. Río, C. H. Polman, and B.M.J. Uitdehaag
Neurology 2008; 70: 1084-1091.
[Abstract]
[Full text]
[PDF]
- ARTICLES
Regression of new gadolinium enhancing lesion activity in relapsing-remitting multiple sclerosis
- Yinshan Zhao, Anthony Traboulsee, A. John Petkau, and David Li
Neurology 2008; 70: 1092-1097.
[Abstract]
[Full text]
[PDF]
|
|
